This Weekend Team ASPS Participated for the 12th Time in the PMC Bike Ride and Continues to Raise Funds to Sponsor Research on ASPS at the Dana Farber Cancer Institute in Boston
Dear ASPS community, this weekend (August 1-2) Team ASPS participated for the 12th time in the Pan-Massachusetts Challenge (PMC).This is a bikea thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. Donations for Team ASPS are restricted for research on ASPS only. I would […]
Important Announcement: CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma
OPEN NOW: CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma Sponsored by: The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust Information provided by: The Institute of Cancer Research – Clinical Trials and Statistics Unit ClinicalTrials.gov Identifier: NCT01337401 Cediranib (AZD2171) is a […]
Thank You Somerset Middle School!
Dear iCureASP Community, I would like to thank the special students and teachers at Somerset Middle School in Wisconsin for their act of kindness and generosity. They made a decision to support the search for the much needed cure for Alveolar Soft Part Sarcoma. Recently in my mailbox I found a donation with the following kind […]
Donate now and support the development of cure for ASPS
We are opening iCureASPS annual fundraiser with the traditional PMC bike ride. Our ASPS team rides yesterday and today for the 10th year at the Pan-Massachusetts Challenge (PMC). Ten years have passed since we founded our group and started to look for a cure for Alveolar Soft Part Sarcoma (ASPS), a rare cancer that has […]
A Summary of Phase II Cederanib Clinical Trial
The summary of the phase 2 clinical trial of Cediranib on Alveolar Soft Part Sarcoma was recently published in the “Journal of Clinical Oncology” by Shivaani Kummar and others from the National Cancer Institute and the Frederick National Laboratory for Cancer Research. The authors report that Cediranib has substantial single-agent activity, producing an objective response […]
The 9th PMC bike ride of “Team ASPS”: More donations for preclinical studies of Alveolar Soft Part Sarcoma
On the first weekend of August 2012, “Team ASPS” participated for the 9th time in the Pan-Massachusetts Challenge (PMC) bike ride. This bike-a-thon crosses Massachusetts to raise money for cancer research and treatment at the Dana-Farber Cancer Institute (DFCI) in Boston. Our team rode 90 miles and raised $30,705 specifically dedicated for finding a cure […]
In Honor of Patti Spires 1967-2012
Patti Spires Hamilton was born at Ft. Meade, Maryland, on September 3, 1967, and passed away in Houston, TX on August 20, 2012. Her life was cut short by Alveolar Soft Part Sarcoma (ASPS), unfortunately undetected and unrecognized by the physicians who treated her for various other “ailments” during the past several years. Patti was […]
Support the annual fundraiser of Team ASPS riding for the 9th year the Pan-Massachusetts Challenge (PMC)
Dear Alveolar Soft Part Sarcoma Community This weekend, August 4-5th 2012, Team ASPS will ride for the 9th time the Pan-Massachusetts Challenge (PMC). The PMC is a bike-a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. As in previous years, I am asking you […]
Update on the Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
If you consider to join the following clinical trial: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma ; study NCT01391962 Please note that patients can join only if: · Patients show evidence of disease progression · Patients must not have received prior treatment with any VEGF receptor tyrosine kinase inhibitor (e.g., cediranib, sunitinib, pazopanib, sorafenib); […]
Important Update on Cediranib development for Alveolar Soft Part Sarcoma (ASPS)
Dear ASPS community. Many of our patients who participated in Cediranib clinical trials reported on our FORUM positive ASPS response to the drug. The conclusion that Cediranib shows favorable activity in ASPS is detailed in a summary of a Phase 2 clinical trial by Dr. Kummar in the 2011 meeting of the American Society of […]